BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16241992)

  • 1. Breast pathology practice: most common problems in a consultation service.
    Putti TC; Pinder SE; Elston CW; Lee AH; Ellis IO
    Histopathology; 2005 Nov; 47(5):445-57. PubMed ID: 16241992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
    Bofin AM; Lydersen S; Hagmar BM
    Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Papillary lesions of the breast: selected diagnostic and management issues.
    Collins LC; Schnitt SJ
    Histopathology; 2008 Jan; 52(1):20-9. PubMed ID: 18171414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Interobserver reproducibility in the pathologic diagnosis of borderline ductal proliferative breast diseases].
    Wei B; Bu H; Zhu CR; Guo LX; Chen HJ; Zhao C; Zhang P; Chen DY; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):849-53. PubMed ID: 15573772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
    Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
    Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
    Rabban JT; Koerner FC; Lerwill MF
    Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillary lesions of the breast.
    Ibarra JA
    Breast J; 2006; 12(3):237-51. PubMed ID: 16684322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture].
    MacGrogan G
    Ann Pathol; 2009 Jun; 29(3):188-93. PubMed ID: 19619824
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of immunohistochemistry in the diagnosis of problematic breast lesions.
    Lee AH
    J Clin Pathol; 2013 Jun; 66(6):471-7. PubMed ID: 23486609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
    Tse GM; Tan PH; Moriya T
    J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast papillomas with atypical ductal hyperplasia: a clinicopathologic study.
    Raju U; Vertes D
    Hum Pathol; 1996 Nov; 27(11):1231-8. PubMed ID: 8912836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artefactual Epithelial Displacement in a Papilloma with Extensive Usual Duct Hyperplasia Mimics a Solid Papillary Carcinoma with Invasive Growth.
    François A; Galant C; Berlière M; Van Bockstal MR
    Int J Surg Pathol; 2021 Jun; 29(4):395-399. PubMed ID: 33736513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
    MacGrogan G; Arnould L; de Mascarel I; Vincent-Salomon A; Penault-Llorca F; Lacroix-Triki M; Bibeau F; Baranzelli MC; Fridman V; Antoine M; Bécette V; Brouste V; Jacquemier J; Mathoulin-Pélissier S;
    Histopathology; 2008 May; 52(6):689-97. PubMed ID: 18397281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of papillary lesions at percutaneous breast biopsy.
    Valdes EK; Tartter PI; Genelus-Dominique E; Guilbaud DA; Rosenbaum-Smith S; Estabrook A
    Ann Surg Oncol; 2006 Apr; 13(4):480-2. PubMed ID: 16474908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant breast lesions that may mimic benign tumors.
    Weidner N
    Semin Diagn Pathol; 1995 Feb; 12(1):2-13. PubMed ID: 7770672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic immunohistochemistry of breast epithelial lesions].
    Balaton AJ; Guinebretière JM; Penault-Llorca F
    Ann Pathol; 2003 Dec; 23(6):570-81. PubMed ID: 15094595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification.
    Pinder SE; Ellis IO
    Breast Cancer Res; 2003; 5(5):254-7. PubMed ID: 12927035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical differentiation of atypical hyperplasia vs. carcinoma in situ of the breast.
    Masood S; Sim SJ; Lu L
    Cancer Detect Prev; 1992; 16(4):225-35. PubMed ID: 1281040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Borderline breast lesions: diagnostic challenges and clinical implications.
    Masood S; Rosa M
    Adv Anat Pathol; 2011 May; 18(3):190-8. PubMed ID: 21490436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ.
    Rosen EL; Smith-Foley SA; DeMartini WB; Eby PR; Peacock S; Lehman CD
    Breast J; 2007; 13(6):545-50. PubMed ID: 17983393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.